Article info
PDFReview
Live attenuated influenza vaccine (LAIV): recent effectiveness results from the USA and implications for LAIV programmes elsewhere
- Correspondence to Dr Richard Pebody, Respiratory Diseases Department, National Infection Service, Public Health England, 61 Colindale Avenue, London, UK; Richard.Pebody{at}phe.gov.uk
Citation
Live attenuated influenza vaccine (LAIV): recent effectiveness results from the USA and implications for LAIV programmes elsewhere
Publication history
- Received March 1, 2017
- Revised July 14, 2017
- Accepted July 19, 2017
- First published August 30, 2017.
Online issue publication
May 18, 2018
Article Versions
- Previous version (13 December 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.